D
셀비온
308430KOSDAQ36.0 / 100
Reference Date: 2026-10-23
Financial Score10.5 / 40
News Sentiment12.5 / 25
Momentum3.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 8.9% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Cellon focuses on developing radiopharmaceuticals using Theranostics technology to realize precision medicine, with Lu-177-Pocuvotide as a key drug for prostate cancer treatment and diagnosis. The company completed phase II clinical trials in South Korea and secured final results by late 2025, leveraging its expertise in designing radiopharmaceuticals targeting various proteins through an open innovation strategy.
Number of Employees
56people
Average Salary
50.8M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
6.92Industry Average 1.200.0Point
5.8x industry avg (risky)
ROE
-28.93Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
44.53Industry Average 100.006.5Point
Half of industry avg (excellent)
Trend 2024~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼15.1% (1-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼15.5% (1-year basis)
ROE Trend
0.0 / 4
Avg ROE -34.1% (improving, 2yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (5%, downtrend)
Current 12,220Won52-week high 40,15052-week low 10,570
1-month return1.0Point
1m -8.94% (falling)
Volume trend1.0Point
Volume dry-up
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral투자판단관련주요경영사항(임상시험계획승인신청등결정) (전이성 거세저항성 전립선암 환자에서 Lutetium(177Lu) DGUL(포큐보타이드 사테트라세탄)의 유효성 및 안전성을 평가하기 위한 다기관, 공개, 무작위배정, 제 3상 임상시험 계획 승인)2026-09-29